Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.

Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF; CD 140 Study Group..

Clin Neuropharmacol. 2012 Sep-Oct;35(5):208-14.

PMID:
22948497
2.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators..

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
3.

Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease.

Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP.

Arch Neurol. 2005 Apr;62(4):554-60.

PMID:
15824252
4.

Interactions between deep brain stimulation and levodopa in Parkinson's disease.

Nutt JG, Rufener SL, Carter JH, Anderson VC, Pahwa R, Hammerstad JP, Burchiel KJ.

Neurology. 2001 Nov 27;57(10):1835-42.

PMID:
11723273
5.

DBS and diathermy interaction induces severe CNS damage.

Nutt JG, Anderson VC, Peacock JH, Hammerstad JP, Burchiel KJ.

Neurology. 2001 May 22;56(10):1384-6.

PMID:
11376192
6.

Assessments of axial motor control during deep brain stimulation in parkinsonian patients.

Robertson LT, Horak FB, Anderson VC, Burchiel KJ, Hammerstad JP.

Neurosurgery. 2001 Mar;48(3):544-51; discussion 551-2.

PMID:
11270544
7.

Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study.

Burchiel KJ, Anderson VC, Favre J, Hammerstad JP.

Neurosurgery. 1999 Dec;45(6):1375-82; discussion 1382-4.

PMID:
10598706
8.

Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group.

Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA.

Arch Neurol. 1998 Sep;55(9):1211-6.

PMID:
9740115
9.

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.

Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF.

Neurology. 1997 Aug;49(2):393-9. Erratum in: Neurology 1997 Nov;49(5):1484.

PMID:
9270567
10.

Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.

Robertson LT, Hammerstad JP.

J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):41-50.

11.

Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis.

Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB.

Neurology. 1995 Mar;45(3 Pt 1):435-9.

PMID:
7898691
12.

Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.

Hammerstad JP, Woodward WR, Nutt JG, Gancher ST, Block GA, Cyhan G.

Clin Neuropharmacol. 1994 Oct;17(5):429-34.

PMID:
9316692
13.

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A.

Neurology. 1994 May;44(5):913-9.

PMID:
8190296
14.

Tendon jerks in Parkinson's disease.

Hammerstad JP, Elliott K, Mak E, Schulzer M, Calne S, Calne DB.

J Neural Transm Park Dis Dement Sect. 1994;8(1-2):123-30.

PMID:
7893374
15.

The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain.

Hammerstad JP, Pate BD, Hewitt KA, Chan GL, Ruth TJ, Calne DB.

Ann Neurol. 1993 Oct;34(4):603-8.

PMID:
8215248
16.

Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.

Nutt JG, Carter JH, Woodward W, Hammerstad JP, Gancher ST.

Mov Disord. 1993 Apr;8(2):139-43.

PMID:
8474479
17.

L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.

Hammerstad JP, Woodward WR, Gliessman P, Boucher B, Nutt JG.

Ann Neurol. 1990 May;27(5):495-9.

PMID:
2360790
18.

Cerebellum plus locus coeruleus in tissue culture. II: Development and metabolism of catecholamines.

Woodward WR, Seil FJ, Hammerstad JP.

J Neurosci Res. 1987;17(2):184-8.

PMID:
3586071
19.

Buspirone in Parkinson's disease.

Hammerstad JP, Carter J, Nutt JG, Casten GC, Shrotriya RC, Alms DR, Temple D.

Clin Neuropharmacol. 1986;9(6):556-60.

PMID:
3026624
20.

Lisuride treatment of focal dystonias.

Nutt JG, Hammerstad JP, Carter JH, deGarmo PL.

Neurology. 1985 Aug;35(8):1242-3.

PMID:
3895034
Items per page

Supplemental Content

Loading ...
Support Center